AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28361468 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP users (participated in the patient support program)
Number of subjects: 1025
Study 28361468 — intervention group
Group type: COMPARATOR
Intervention: PSP non-users (did not participate in the patient support program)
Number of subjects: 1025
Study 28361468 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP users
Number of subjects: 1025
Study 28363153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureido-substituted benzenesulfonamides (USBs)
Number of subjects: 0
Study 28363153 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC-0111/U-F
Number of subjects: 0
Study 28363153 — intervention group
Group type: EXPERIMENTAL
Intervention: hCA II (off-target) and hCA IX-mimic (target)
Number of subjects: 0
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed influenza diagnosis
Number of subjects: 501
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Other respiratory viruses
Number of subjects: 501
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection with influenza and another respiratory virus
Number of subjects: 501
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus types
Number of subjects: 501
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct medical costs associated with laboratory-confirmed influenza
Number of subjects: 501
Study 28363360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine administration
Number of subjects: 501
Study 28363682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) during PCI-S
Number of subjects: 0
Study 28363682 — intervention group
Group type: COMPARATOR
Intervention: Non-low bleeding risk group
Number of subjects: 0
Study 28363682 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-low bleeding risk category
Number of subjects: 0
Study 28363682 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0
Study 28363725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia procedures
Number of subjects: 30874
Study 28363827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 226
Study 28363827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of predictive parameters (DAS28, IFN score, DMARD use)
Number of subjects: 226
Study 28363920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined piped water and sanitation intervention
Number of subjects: 90
Study 28364045 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 mapping
Number of subjects: 73
Study 28364045 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 73
Study 28364045 — intervention group
Group type: COMPARATOR
Intervention: T2-weighted short tau inversion recovery (T2W-STIR)
Number of subjects: 73
Study 28364198 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sedation using propofol TCI
Number of subjects: 43
Study 28364214 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust patients
Number of subjects: 1280
Study 28364214 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 1280
Study 28364214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail patients
Number of subjects: 1280
Study 28364214 — intervention group
Group type: COMPARATOR
Intervention: Robust patients receiving chemotherapy
Number of subjects: 1280
Study 28364368 — intervention group
Group type: EXPERIMENTAL
Intervention: User fees for GP consultations
Number of subjects: 343
Study 28364381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with Methotrexate (MTX)
Number of subjects: 157
Study 28364381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with low-dose MTX (<8 mg/week)
Number of subjects: 157
Study 28364381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with high-dose MTX (≥8 mg to ≤16 mg/week)
Number of subjects: 157
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake on BL1 and BL2
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake on BL1 and BL2
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater fat-free mass
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body fat percentage
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overweight (BMI 25-30)
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater fiber consumption on BL1 and BL2
Number of subjects: 50
Study 28364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake the following day (BL2)
Number of subjects: 50
Study 28364479 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring during weaning from CPB
Number of subjects: 23
Study 28364479 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal myocardial function classification via accelerometer
Number of subjects: 23
Study 28364479 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) stroke work and systolic velocity by echocardiography
Number of subjects: 23
Study 28364495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexsomnia patients
Number of subjects: 17
Study 28364495 — intervention group
Group type: COMPARATOR
Intervention: Sleepwalkers
Number of subjects: 17
Study 28364869 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR (low-dose 17β-estradiol vaginal softgel capsule)
Number of subjects: 0
Study 28365080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition therapy (NT)
Number of subjects: 351
Study 28365080 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 351
Study 28365204 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based training with body-controlled videogames
Number of subjects: 10
Study 28366306 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine infusion
Number of subjects: 22
Study 28366342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (0.5, 1, 2, 3 mg/24 h) applied daily and up-titrated weekly.
Number of subjects: 24
Study 28366441 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 112
Study 28366441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping biopsies
Number of subjects: 112
Study 28366441 — intervention group
Group type: COMPARATOR
Intervention: High-definition white-light (HD-WL) endoscopy
Number of subjects: 112
Study 28367260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of Botulinum Toxin A
Number of subjects: 0
Study 28367260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of Botulinum Toxin A
Number of subjects: 0
Study 28367260 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28357039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive practice
Number of subjects: 0
Study 28367334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (Spin)
Number of subjects: 32
Study 28367334 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic exercise control (Balance)
Number of subjects: 32
Study 28367426 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs implantation (20-50×10^6 MSCs)
Number of subjects: 5
Study 28367426 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs implantation
Number of subjects: 5
Study 28368443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous kisspeptin infusion (12.5 µg/kg/h) over 24 hours
Number of subjects: 8
Study 28368443 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin (0.313 µg/kg) and GnRH (75 ng/kg) intravenous boluses
Number of subjects: 8
Study 28368516 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIGIN biomarker panel
Number of subjects: 350
Study 28368516 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI levels
Number of subjects: 350
Study 28368516 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIGIN biomarkers
Number of subjects: 350
Study 28368516 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI levels added to ORIGIN models
Number of subjects: 350
Study 28368743 — intervention group
Group type: EXPERIMENTAL
Intervention: IV VRC01 (10, 20, 30 or 40 mg/kg) every 4 or 8 weeks
Number of subjects: 84
Study 28368743 — intervention group
Group type: EXPERIMENTAL
Intervention: SC VRC01 (5 mg/kg) every 2 weeks
Number of subjects: 84
Study 28368743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg 8-weekly regimen
Number of subjects: 84
Study 28368743 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg 8-weekly regimen
Number of subjects: 84
Study 28369210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 106
Study 28369303 — intervention group
Group type: EXPERIMENTAL
Intervention: TAo-first
Number of subjects: 301
Study 28369303 — intervention group
Group type: COMPARATOR
Intervention: TAo-last
Number of subjects: 301
Study 28369329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously (IV) every 4 weeks
Number of subjects: 68
Study 28369341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fecal microbiota transplantation (FMT)
Number of subjects: 20
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 5 mg
Number of subjects: 24
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 10 mg
Number of subjects: 24
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 24
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (all doses)
Number of subjects: 24
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro tenofovir-dp formation
Number of subjects: 24
Study 28369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide dosing in vivo
Number of subjects: 24
Study 28369553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 24
Study 28370090 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 308
Study 28370090 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 308
Study 28370350 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir/asunaprevir/beclabuvir (DCV-TRIO) 30 mg, 200 mg, and 75 mg respectively, administered twice daily for 12 weeks.
Number of subjects: 169
Study 28370444 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 481
Study 28370677 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function assessment using Sniffin' Sticks Extended Test in MCI individuals
Number of subjects: 85
Study 28370677 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory identification score in MCI individuals
Number of subjects: 85
Study 28370677 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) assessment in MCI individuals
Number of subjects: 85
Study 28370677 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study 28371297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention program 'DiOGenes'
Number of subjects: 473
Study 28372575 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic assessment of respiratory mechanics (bedside measurements)
Number of subjects: 61
Study 28372575 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-assessment ventilator settings
Number of subjects: 61
Study 28372865 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese adolescents
Number of subjects: 20
Study 28372865 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight adolescents
Number of subjects: 20
Study 28373005 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity
Number of subjects: 184
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 1 mg/kg
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (all doses)
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg and 20 mg/kg)
Number of subjects: 53
Study 28373007 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (3 mg/kg and 10 mg/kg)
Number of subjects: 53
Study 28373069 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib therapy
Number of subjects: 1669
Study 28373243 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance at baseline
Number of subjects: 100
Study 28373243 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up scans at 6 months postpartum
Number of subjects: 100
Study 28373243 — intervention group
Group type: EXPERIMENTAL
Intervention: Death/transplant rates at 12 months
Number of subjects: 100
Study 28373243 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cardiovascular magnetic resonance scans
Number of subjects: 100
Study 28373258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalised patients with intra-abdominal infection, pneumonia, complicated urinary tract infections, and bloodstream infections caused by CRE
Number of subjects: 202
Study 28373258 — intervention group
Group type: COMPARATOR
Intervention: Patients with carbapenem-susceptible infections (matched control group)
Number of subjects: 202
Study 28373262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib at a once-daily dose of 420 mg
Number of subjects: 0
Study 28373262 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower dose intensity)
Number of subjects: 0
Study 28373269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (<120 mm Hg)
Number of subjects: 9361
Study 28373269 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (<140 mm Hg)
Number of subjects: 9361
Study 28373849 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0
Study 28374214 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage for diabetes cohort
Number of subjects: 1998
Study 28374214 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage for hypertension cohort
Number of subjects: 1998
Study 28374214 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage for hyperlipidemia cohort
Number of subjects: 1998
Study 28374496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 166
Study 28374496 — intervention group
Group type: COMPARATOR
Intervention: Entecavir hydrate (ETV) 0.5 mg
Number of subjects: 166
Study 28375658 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin single-pill combination therapy
Number of subjects: 0
Study 28375658 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin or linagliptin as first-line treatment
Number of subjects: 0
Study 28375789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% preservative-free zinc-hyaluronate
Number of subjects: 20
Study 28375876 — intervention group
Group type: COMPARATOR
Intervention: Bone conduction hearing aid + NH condition
Number of subjects: 20
Study 28375876 — intervention group
Group type: EXPERIMENTAL
Intervention: CI + NH condition
Number of subjects: 20
Study 28375876 — intervention group
Group type: COMPARATOR
Intervention: NH-alone condition
Number of subjects: 20
Study 28376109 — intervention group
Group type: COMPARATOR
Intervention: NAFLD
Number of subjects: 320
Study 28376109 — intervention group
Group type: COMPARATOR
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 320
Study 28376109 — intervention group
Group type: EXPERIMENTAL
Intervention: LECT2 levels
Number of subjects: 320
Study 28376109 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of LECT2 levels
Number of subjects: 320
Study 28376316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin added to chemotherapy
Number of subjects: 477
Study 28376728 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq on fresh-frozen (FF) specimens
Number of subjects: 21
Study 28376728 — intervention group
Group type: COMPARATOR
Intervention: RNA-seq on formalin-fixed paraffin-embedded (FFPE) specimens
Number of subjects: 21
Study 28376739 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence of Bordetella pertussis antibodies in adults
Number of subjects: 0
Study 28376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of maximal CCA wall thickness to median IMT
Number of subjects: 240
Study 28376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CCA thickness parameter values
Number of subjects: 240
Study 28376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of wall thickness and diameter
Number of subjects: 240
Study 28376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of maximal wall thickness to end-diastolic diameter
Number of subjects: 240
Study 28376799 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 69
Study 28376837 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Number of subjects: 50
Study 28376908 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II score
Number of subjects: 5266
Study 28376908 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS 3 score
Number of subjects: 5266
Study 28377399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo models of DBA
Number of subjects: 0
Study 28377958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 25 μg vitamin D supplementation
Number of subjects: 251
Study 28377958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 28378429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (change in diet and cardiovascular fitness)
Number of subjects: 699
Study 28378429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (change in diet)
Number of subjects: 699
Study 28378429 — intervention group
Group type: COMPARATOR
Intervention: Increased sweetened beverage intake
Number of subjects: 699
Study 28378544 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole orally once daily for 8 days
Number of subjects: 24
Study 28378561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-pinhole (MPH) glasses
Number of subjects: 36
Study 28378561 — intervention group
Group type: COMPARATOR
Intervention: Single-pinhole (SPH) glasses
Number of subjects: 36
Study 28378561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MPH and SPH glasses
Number of subjects: 36
Study 28378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 64
Study 28379370 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Specimen Diversion Device (ISDD)
Number of subjects: 904
Study 28379370 — intervention group
Group type: COMPARATOR
Intervention: Standard phlebotomy procedures
Number of subjects: 904
Study 28379401 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric wall thickening detected by magnetic resonance
Number of subjects: 166
Study 28379401 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric wall thickening detected by echocardiography
Number of subjects: 166
Study 28379401 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cardiac troponin I and brain natriuretic peptide concentrations
Number of subjects: 166
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased baseline BMI
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase by 3 and 5 years
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BMI in pre-menopausal endocrine therapy trial MA.12
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI in pre-menopausal endocrine therapy trial MA.12
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI in post-menopausal endocrine therapy trials MA.14 and MA.27
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean increased BMI of 0.3 in post-menopausal endocrine therapy trials MA.14 and MA.27
Number of subjects: 2793
Study 28379421 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI and BMI change in trastuzumab administration
Number of subjects: 2793
Study 28379427 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg once daily subcutaneously for 21 days
Number of subjects: 10
Study 28379580 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term lifestyle intervention
Number of subjects: 330
Study 28379878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24
Study 28379878 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 24
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (MA)
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≤8 years
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration ≤1 month
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional lymphadenopathy
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence <90%
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Z-score of height/age (in children)
Number of subjects: 230
Study 28379954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (MA) (in children)
Number of subjects: 230
Study 28380308 — intervention group
Group type: EXPERIMENTAL
Intervention: PiMZ genotype
Number of subjects: 8271
Study 28380308 — intervention group
Group type: COMPARATOR
Intervention: Z-allele noncarriers
Number of subjects: 8271